RAGE: a novel biological and genetic marker for vascular disease.
about
Advanced Glycation End Products: Link between Diet and Ovulatory Dysfunction in PCOS?Biomarkers in diabetes: hemoglobin A1c, vascular and tissue markersRelationship between Advanced Glycation End Products and Steroidogenesis in PCOSEarly progression of diabetic nephropathy correlates with methylglyoxal-derived advanced glycation end productsThe RAGE axis: a fundamental mechanism signaling danger to the vulnerable vasculatureHigher plasma soluble Receptor for Advanced Glycation End Products (sRAGE) levels are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study.Alternatively spliced RAGEv1 inhibits tumorigenesis through suppression of JNK signalingGlyco-oxidation and cardiovascular complications in type 2 diabetes: a clinical updateAssociation of serum soluble receptor for advanced glycation end-products with subclinical cerebrovascular disease: the Northern Manhattan Study (NOMAS)An interactive association of advanced glycation end-product receptor gene four common polymorphisms with coronary artery disease in northeastern Han Chinese.Alternative splicing of the RAGE cytoplasmic domain regulates cell signaling and function.Impact of serum high mobility group box 1 and soluble receptor for advanced glycation end-products on subclinical atherosclerosis in patients with granulomatosis with polyangiitis.Total soluble and endogenous secretory receptor for advanced glycation end products as predictive biomarkers of coronary heart disease risk in patients with type 2 diabetes: an analysis from the CARDS trialSerum levels of soluble receptor for advanced glycation end-products and metabolic syndrome: the Northern Manhattan StudyGenetics of Plasma Soluble Receptor for Advanced Glycation End-Products and Cardiovascular Outcomes in a Community-based Population: Results from the Atherosclerosis Risk in Communities StudySerum Level of Soluble Receptor for Advanced Glycation End Products Is Associated with A Disintegrin And Metalloproteinase 10 in Type 1 DiabetesAdaptive evolution of the MHC class III-encoded receptor RAGE in primates and murine rodents.Polymorphisms in three genes are associated with hemorrhagic stroke.Plantar fascia thickness is longitudinally associated with retinopathy and renal dysfunction: a prospective study from adolescence to adulthoodThe Mouse-Specific Splice Variant mRAGE_v4 Encodes a Membrane-Bound RAGE That Is Resistant to Shedding and Does Not Contribute to the Production of Soluble RAGE.Neuroprotective Effect of 3-(Naphthalen-2-Yl(Propoxy)Methyl)Azetidine Hydrochloride on Brain Ischaemia/Reperfusion Injury.Association of 2184AG Polymorphism in the RAGE Gene with Diabetic Nephropathy in Chinese Patients with Type 2 Diabetes.Early release of soluble receptor for advanced glycation endproducts after severe trauma in humans.Association of the receptor for advanced glycation end-products (RAGE) gene polymorphisms in Malaysian patients with chronic kidney disease.Serum soluble RAGE levels and carotid atherosclerosis: the Northern Manhattan Study (NOMAS).Dietary Advanced Glycation End Products and Their Potential Role in Cardiometabolic Disease in Children.Plasma levels of soluble receptor for advanced glycation end products and coronary atherosclerosis: possible correlation with clinical presentation.Plasma Levels of Pentosidine, Carboxymethyl-Lysine, Soluble Receptor for Advanced Glycation End Products, and Metabolic Syndrome: The Metformin Effect.Gene expression ratio test distinguishes normal lung from lung tumors in solid tissue and FNA biopsies.An inverse association between serum soluble receptor of advanced glycation end products and hyperandrogenism and potential implication in polycystic ovary syndrome patients.Reduced soluble receptor for advanced glycation end-products (sRAGE) scavenger capacity precedes pre-eclampsia in Type 1 diabetes.Glycation and biomarkers of vascular complications of diabetes.RAGE biology, atherosclerosis and diabetes.Receptor for advanced glycation end products (RAGE) and implications for the pathophysiology of heart failure.Danger signals activating the immune response after trauma.Involvement of inflammatory factors in pancreatic carcinogenesis and preventive effects of anti-inflammatory agents.Baking, ageing, diabetes: a short history of the Maillard reaction.Association between the RAGE gene -374T/A, -429T/C polymorphisms and diabetic nephropathy: a meta-analysis.Reasons to Investigate the Soluble Receptor for Advanced Glycation End-Product (sRAGE) Pathway in Aortic Disease.Targeting the Receptor for Advanced Glycation Endproducts (RAGE): A Medicinal Chemistry Perspective.
P2860
Q26774333-DB7C0E84-9D26-4F2A-9032-E6FC73C732BBQ26996480-5114B47B-D374-489A-97F1-DA7CF4191D83Q28077960-18C09F09-4779-4078-9754-3A98543FDBF2Q30410401-D9D4A291-3F76-4D98-8EDF-EBF0550665E8Q33822512-0B237E93-17D9-4A03-946F-F7F6D225ADEFQ34024272-E68B9B10-B5E3-4523-9FB1-53F46252F657Q34056610-0D59F9C8-F756-409D-B127-5EC2A01FC93BQ34286094-2E4D1CBD-2CB4-4674-9F5F-B6714C17A44DQ34949171-7503BF0A-7EAB-4908-A1E3-66D27B0A7105Q35025330-883AFB04-7305-41F1-9322-784DD17EBF17Q35048039-A3BA3C3B-D5C1-447B-B48A-6BE0577387A4Q35158943-7D1AEBA4-F860-4CE5-8CBB-4AC72AD19DB9Q35180065-3852E54A-5E25-4691-8A39-DC64FAD04911Q35234754-FDFE0BE0-5DF5-4301-9215-B71F13709FA9Q35666321-FCC6681B-39D4-49FC-9304-AA74B64D828FQ35760856-FD546620-5787-46CA-9580-53C2CAA00AEAQ35780980-ED607E2F-A3F1-4154-B8FB-DCCFCF73399EQ35868148-689BB529-E366-4CC1-B19C-1108B9F2937BQ36051272-527405A0-3342-456C-A8D3-AA1ACFE54D1FQ36139994-D311ABC1-2822-46C4-8B09-43B7B10800CBQ36293417-48BFB37D-FE4C-48B4-9DDB-37864F735616Q36378760-B7A3E077-5E39-41FF-8711-920CA5DB22BFQ36493417-2FA230BA-CCFE-4A29-9DA7-09F82B365A6AQ36826342-D78F9691-ABC8-49F6-B514-D787B791F313Q36935766-AE5F3592-C790-420A-85DE-E355C4AB16A5Q36963380-D43B9751-DF7F-4795-986B-F31D286134E1Q37176678-F98A34F3-A7A6-478D-9C5F-7C4145A20A34Q37382495-3AA26D4A-A13B-4ADF-AE9B-80820F81FE9EQ37608246-0BC21AF1-F375-40C4-A29D-F34B22B53E1CQ37609701-72B949ED-1607-4ABC-B380-919150DCBB03Q37693552-9C229D70-06A4-4579-94FE-FE4C17EB9AAAQ37806134-EFFE3234-3E95-49D5-95FF-DA8C02ED495EQ37860348-5E7E4DBD-13CC-4554-8C1F-01D92FBAD001Q37997993-01ECE17F-1748-4B56-B87D-6290CF33C480Q38025082-33A9F2F5-07B8-42B8-995D-A80D395178FEQ38041420-C054B207-11EC-4C03-88C7-F8B86492AB3AQ38232036-866662EA-8778-480B-9425-C4BF15C8F674Q38364408-D1DD6D9F-DE50-496B-A4BE-40587BDB0D9DQ38370045-9A60D46B-46F7-4F3C-A9A1-CD8720C89384Q38686477-48E6C268-5C7C-4014-A70F-6DF1F334B4F4
P2860
RAGE: a novel biological and genetic marker for vascular disease.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
RAGE: a novel biological and genetic marker for vascular disease.
@en
RAGE: a novel biological and genetic marker for vascular disease.
@nl
type
label
RAGE: a novel biological and genetic marker for vascular disease.
@en
RAGE: a novel biological and genetic marker for vascular disease.
@nl
prefLabel
RAGE: a novel biological and genetic marker for vascular disease.
@en
RAGE: a novel biological and genetic marker for vascular disease.
@nl
P356
P1433
P1476
RAGE: a novel biological and genetic marker for vascular disease
@en
P2093
Ann Marie Schmidt
P304
P356
10.1042/CS20080494
P407
P577
2009-04-01T00:00:00Z